Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Hemostemix ( (TSE:HEM) ).
Hemostemix Inc. has closed the final tranche of its non-brokered private placement, raising $303,967.80 through the issuance of 2,533,065 common shares at $0.12 per share, bringing total gross proceeds from the financing to approximately $783,967. The company plans to use the funds for general working capital, including advancing regulatory, clinical, and commercialization initiatives for its ACP-01 (VesCell) autologous angiogenic cell therapy platform, while the offering remains subject to final TSX Venture Exchange acceptance.
The capital injection supports Hemostemix’s efforts to scale and commercialize its stem cell therapy portfolio, reinforcing its positioning in regenerative medicine targeting severe ischemic and cardiac conditions. Positive clinical data to date, including strong outcomes in chronic limb threatening ischemia, underscore the potential strategic importance of ACP-01 to the company’s growth trajectory and to stakeholders focused on innovative treatments for high-mortality vascular disease.
The most recent analyst rating on (TSE:HEM) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Hemostemix stock, see the TSE:HEM Stock Forecast page.
Spark’s Take on HEM Stock
According to Spark, TipRanks’ AI Analyst, HEM is a Neutral.
The score is weighed down primarily by very weak financial performance (no revenue, ongoing losses, rising recent cash burn, and negative equity/solvency risk). Technicals add modest support from short-term trend strength, but valuation remains unattractive/unclear due to negative earnings and no dividend.
To see Spark’s full report on HEM stock, click here.
More about Hemostemix
Hemostemix Inc. is a Calgary-based autologous stem cell therapy company focused on treating ischemic and cardiovascular conditions such as peripheral arterial disease, chronic limb threatening ischemia, cardiomyopathies, congestive heart failure, angina, total body ischemia, and vascular dementia. Founded in 2003 and a recipient of the World Economic Forum Technology Pioneer Award, it has developed and patented VesCell (ACP-01), a blood-based angiogenic cell therapy platform that has been evaluated in seven clinical studies involving 318 subjects, with results published in multiple peer-reviewed journals pointing to its safety and clinical relevance.
Average Trading Volume: 66,562
Technical Sentiment Signal: Sell
Current Market Cap: C$15.62M
Find detailed analytics on HEM stock on TipRanks’ Stock Analysis page.